KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $982.8 million.

  • Regeneron Pharmaceuticals' Share-based Compensation rose 5.29% to $237.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 14.15%. This contributed to the annual value of $982.8 million for FY2024, which is 11.05% up from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' Share-based Compensation is $982.8 million, which was up 11.05% from $885.0 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Share-based Compensation registered a high of $982.8 million during FY2024, and its lowest value of $432.0 million during FY2020.
  • Its 3-year average for Share-based Compensation is $864.3 million, with a median of $885.0 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first declined by 6.96% in 2020, then surged by 39.28% in 2021.
  • Regeneron Pharmaceuticals' Share-based Compensation (Yearly) stood at $432.0 million in 2020, then spiked by 39.28% to $601.7 million in 2021, then climbed by 20.49% to $725.0 million in 2022, then rose by 22.07% to $885.0 million in 2023, then rose by 11.05% to $982.8 million in 2024.